Cargando…

Single-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Wang, Xinfeng, Li, Yuan, Jin, Runsen, Zheng, Sufei, Luo, Yuejun, Wu, Peng, Wang, Zhanyu, Yao, Yuxin, Sun, Nan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837066/ https://www.ncbi.nlm.nih.gov/pubmed/36635267 http://dx.doi.org/10.1038/s41392-022-01226-1

Ejemplares similares

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma
por: Liu, Chengming, et al.
Publicado: (2022)

The TGFβ-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis
por: Zheng, Sufei, et al.
Publicado: (2019)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Tumor‐infiltrating CD8(+) T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited‐stage small cell esophageal carcinoma
por: Zhang, Zhihui, et al.
Publicado: (2021)

Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
por: Huang, Tingting, et al.
Publicado: (2020)

Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity
por: Zang, Ruochuan, et al.
Publicado: (2019)

Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer
por: Mao, Shuangshuang, et al.
Publicado: (2020)

ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
por: lei, Yuanyuan, et al.
Publicado: (2020)

The landscape of m(6)A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
por: Zhang, Chaoqi, et al.
Publicado: (2021)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
por: Yang, Guangjian, et al.
Publicado: (2022)

Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1
por: Mao, Shuangshuang, et al.
Publicado: (2021)

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
por: Yang, Yaning, et al.
Publicado: (2023)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis
por: Lu, Zhiliang, et al.
Publicado: (2021)

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
por: Mao, Shiqi, et al.
Publicado: (2023)

Combined detection of aneuploid circulating tumor‐derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non‐small‐cell lung cancer
por: Lei, Yuanyuan, et al.
Publicado: (2020)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
por: Chen, Hao, et al.
Publicado: (2023)

Clusterin modulates transdifferentiation of non-small-cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2017)

Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
por: Wu, Yanyan, et al.
Publicado: (2020)

Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report
por: Ni, Jun, et al.
Publicado: (2021)

Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients
por: He, Jiangping, et al.
Publicado: (2020)

Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection
por: Zang, Ruochuan, et al.
Publicado: (2019)

Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer
por: Wu, Peng, et al.
Publicado: (2022)

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2(+) Breast Cancer Cells to 5-Fluorouracil
por: Yi, Jianing, et al.
Publicado: (2020)

Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2(+) breast cancer with brain metastasis: a retrospective cohort study
por: Chen, Jiaxin, et al.
Publicado: (2022)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
por: Zhang, Miao, et al.
Publicado: (2022)

The potential role of N(7)-methylguanosine (m7G) in cancer
por: Luo, Yuejun, et al.
Publicado: (2022)

Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC
por: Han, Xiao, et al.
Publicado: (2022)

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
por: Tian, Yanhua, et al.
Publicado: (2022)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
por: Wang, Li, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r9q80gbp5rai96vvr74r22d6q1